A recent study published in the International Journal of Radiation Oncology assessed survival rates of metastatic brain tumor patients treated with stereotactic radiosurgery (SRS) alone, compared to those treated with a combination of SRS and whole-brain radiation therapy (WBRT).
Researchers analyzed patient data from three of the largest clinical trials of SRS and WBRT conducted to-date. The patients involved in the study were all under the age of 50 and had limited brain metastases of one to four tumors.
The study found that there was a 13 percent increase in the patient survival rate for those who received SRS alone, compared to patients who received both SRS and WBRT.
“We expected to see a survival advantage favoring combined therapy of SRS and WBRT. However, these data clearly demonstrate the benefit for SRS alone to improve survival for our younger patients with limited brain metastases,” said lead author Dr. Arjun Sahgal.
To read more about the study and results, click here.
If interested in learning more about stereotactic radiosurgery at Oklahoma CyberKnife, visit our conditions treated page for information about CyberKnife® SRS treatment for primary brain tumors and brain metastases.
This is not intended as medical advice to replace the expertise and judgment of your health care team. It is intended to help you and your family make informed decisions, together with your doctor.